Expert clinical framework report: Management of adverse events related to novel therapies for
relapsed/refractory multiple myeloma (RRMM) | Canadian Hematology Today Skip to main …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Abstract Purpose of Review The purpose of this review was to evaluate management
strategies for common adverse effects of novel therapies in multiple myeloma (MM) …

The combination of conventional chemotherapy or dexamethasone with new drugs, such as
immunomodulatory agents and proteasome inhibitors, has substantially changed the …

Background Several new treatment options have been approved for relapsed and/or
refractory multiple myeloma (RRMM). In this systematic review, associations of the efficacy of …

Therapeutic options for patients with multiple myeloma have multiplied in the past decade.
However, multiple myeloma remains an incurable disease, and relapsed/refractory myeloma …

Introduction: Limited real-world data exist on treatments for relapsed/refractory multiple
myeloma (RRMM) since the approval of several new agents. This study assessed treatment …

Improved understanding as to the biology of multiple myeloma (MM) and the bone marrow
microenvironment has led to the development of new drugs to treat MM. This explosion of …

Despite advances in therapies for multiple myeloma, a majority of the patients relapse after
front‐line therapy. The management of relapsed/refractory multiple myeloma has become …

Introduction: In the last decade, the availability of new drugs for the treatment of Multiple
Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a …